CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Newsroom

Press releases and media contact.

Press releases

Get news alerts →
October 1, 2026
Platform & partnering
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake™ Pharmaceutical 3D Printing Platform
August 18, 2026
Platform & partnering
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for its Personalized Medicine and Peptide Platform, PERSONALIZ3D™
August 11, 2026
Platform & partnering
PharmaTher Establishes PERSONALIZ3D™ to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
July 29, 2026
Platform & partnering
PharmaTher Collaborates with Craft Health to Evaluate CraftMake™ GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
July 27, 2026
Platform & partnering
PharmaTher Launches Personaliz3D Peptides™ to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
July 21, 2026
Platform & partnering
PharmaTher Enters into Collaboration Agreement for KetaMist® to Advance Needle-Free Ketamine Treatment Toward FDA Approval
July 15, 2026
Pipeline
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
May 27, 2026
Platform & partnering
PharmaTher Evolves Platform Strategy with MEDBOTX™ Robotic 3D Printing for Personalized Medicines
May 13, 2026
Pipeline
PharmaTher’s Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
April 21, 2026
Pipeline
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
April 20, 2026
Platform & partnering
PharmaTher’s Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
April 16, 2026
Platform & partnering
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
April 13, 2026
Pipeline
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
March 26, 2026
Pipeline
PharmaTher Introduces PatchPrint™ With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
March 3, 2026
Platform & partnering
PharmaTher Expands PharmaPatch™ Delivery Platform into Therapeutic Peptides for the U.S. Market
February 2, 2026
Financial
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
January 14, 2026
Platform & partnering
PharmaTher Expands PharmaPatch™ Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
January 2, 2026
Financial
PharmaTher CEO Publishes Letter to Shareholders
December 2, 2025
Financial
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
November 17, 2025
Platform & partnering
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

All PharmaTher press releases since October 2020, newest first.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.